Study to Assess the Adverse Events of Oral ABBV-932 in Adult Participants With Depressive Episodes Associated With Bipolar I or II Disorder

Active, not recruiting · Phase 2 · NCT07220460

Conditions: Bipolar I or II Disorder

Research payments reported, 2025: $163,544
U.S. investigators named: 41
Sites paid: 41
Planned or actual enrollment: 84

About the trial

Sponsor: AbbVie
Tested: ABBV-932 (drug)
Dates: Started 2025-09-30; completion 2027-04
Results posted: Not yet

Bipolar disorder is a severe chronic mood disorder that affects up to 4% of the adult population in the United States. The purpose of this study is to assess how safe and effective ABBV-932 is in treating participants with depressive episodes associated with bipolar I or II disorder. ABBV-932 is an investigational drug being developed for the treatment of depressive episodes in adult participants with bipolar I or II disorder. Participants with bipolar I or II disorder who are currently experiencing a depressive episode will enter the study and be treated with open-label ABBV-932. Approximately 200 adult participants with bipolar I or II disorder will be enrolled in approximately 50 sites…

From ClinicalTrials.gov, last updated 2026-09-23. Full record, eligibility and contacts (opens in a new tab)

Industry funding

AbbVie Inc. reported $163,544 in research payments for this study in 2025 (52 payments).

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.

At a glance

About the trial

Industry funding

U.S. investigators named on this study

Sites paid to run it